Who owns ACELRX PHARMACEUTICALS INC?
- Ticker: TLPH
- CUSIP Number: 00444t209
Tip: Access positions for across all investors
Analyze quarterly positions in Acelrx Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Acelrx Pharmaceuticals stock
Who bought or sold ACELRX PHARMACEUTICALS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| AIGH Capital Management | 4.7M | $3.5M | 0% | Mar 2026 |
|
| Rock Springs Capital Management | 3.6M | $2.7M | 0% | Mar 2026 |
|
| Rosalind Advisors | 3.6M | $4.1M | -18% | Dec 2025 |
|
| Nantahala Capital Management | 3.5M | $2.6M | 0% | Mar 2026 |
|
| Cantor Fitzgerald, L. P. | 888k | $663k | 54% | Mar 2026 |
|
| Bleichroeder | 881k | $1.0M | 0% | Dec 2025 |
|
| Caption Management | 800k | $912k | 220% | Dec 2025 |
|
| Vanguard Group | 664k | $757k | 132% | Dec 2025 |
|
| Empery Asset Management | 591k | $441k | -56% | Mar 2026 |
|
| Dauntless Investment Group | 579k | $660k | 479% | Dec 2025 |
|
| Almitas Capital | 467k | $349k | 100% | Mar 2026 |
|
| Vanguard Capital Management | 442k | $330k | 100% | Mar 2026 |
|
| Geode Capital Management | 420k | $314k | 22% | Mar 2026 |
|
| Susquehanna International | 280k | $320k | 2426% | Dec 2025 |
|
| Renaissance Technologies | 257k | $293k | 413% | Dec 2025 |
|
| Shay Capital | 250k | $187k | 100% | Mar 2026 |
|
| Citadel Advisors | 217k | $162k | 9% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 192k | $144k | 100% | Mar 2026 |
|
| Diadema Partners | 137k | $156k | 100% | Dec 2025 |
|
| Mariner Wealth Advisors | 100k | $75k | 72% | Mar 2026 |
|
| GSA Capital Partners | 94k | $70k | 347% | Mar 2026 |
|
| BlackRock | 92k | $68k | 0% | Mar 2026 |
|
| Simplex Trading | 86k | $98k | 6893% | Dec 2025 |
|
| Values First Advisors | 82k | $61k | 0% | Mar 2026 |
|
| Northern Trust | 53k | $60k | 383% | Dec 2025 |
|
| Jane Street | 47k | $35k | -83% | Mar 2026 |
|
| Persistent Asset Partners | 39k | $29k | 6% | Mar 2026 |
|
| Vanguard Global Advisers | 30k | $22k | 100% | Mar 2026 |
|
| State Street Corporation | 22k | $25k | 0% | Dec 2025 |
|
| AlphaCore Capital | 21k | $15k | 100% | Mar 2026 |
|
| Hrt Financial | 19k | $14k | 100% | Mar 2026 |
|
| Two Sigma Securities | 19k | $14k | 100% | Mar 2026 |
|
| UBS Group | 14k | $10k | 103% | Mar 2026 |
|
| Onyx Bridge Wealth Group | 12k | $8.6k | 0% | Mar 2026 |
|
| Group One Trading | 6.7k | $5.0k | -88% | Mar 2026 |
|
| MAI Wealth Advisors | 3.3k | $2.5k | 0% | Mar 2026 |
|
| Tower Research Capital | 2.8k | $3.2k | -55% | Dec 2025 |
|
| Wells Fargo & Company | 983.00 | $734.006100 | 0% | Mar 2026 |
|
| Silicon Valley Capital Partners | 137.00 | $101.996500 | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 136.00 | $102.000000 | 0% | Mar 2026 |
|
| SBI Securities | 113.00 | $84.004200 | 45% | Mar 2026 |
|
| SRS Capital Advisors | 81.00 | $61.001100 | 0% | Mar 2026 |
|
| Global Retirement Partners | 23.00 | $25.999200 | -68% | Dec 2025 |
|
| Dogwood Wealth Management | 10.00 | $7.000000 | 0% | Mar 2026 |
|
| Morgan Stanley | 10.00 | $7.000000 | 0% | Mar 2026 |
|
Who sold out of Acelrx Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Virtu Financial | Sep 2025 | 33k | $29k |
| Two Sigma Investments | Dec 2025 | 25k | $28k |
| Advisor Group Holdings | Sep 2025 | 26.00 | $14.001000 |